{"id":650883,"date":"2026-01-09T04:06:11","date_gmt":"2026-01-09T04:06:11","guid":{"rendered":"https:\/\/www.europesays.com\/fr\/650883\/"},"modified":"2026-01-09T04:06:11","modified_gmt":"2026-01-09T04:06:11","slug":"quand-trump-fait-exploser-le-lobby-du-medicament-en-france","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/fr\/650883\/","title":{"rendered":"Quand Trump fait exploser le lobby du m\u00e9dicament en France"},"content":{"rendered":"

\n Un nouveau syndicat de l\u2019industrie pharmaceutique en France s\u2019appr\u00eate \u00e0 voir le jour pour d\u00e9fendre les int\u00e9r\u00eats du secteur.<\/p>\n

Les contraintes budg\u00e9taires fran\u00e7aises<\/a>\u00a0et la\u00a0pression exerc\u00e9e par Donald Trump<\/a>\u00a0pour que les laboratoires investissent aux \u00c9tats-Unis auront eu raison de l\u2019unit\u00e9 du lobby du m\u00e9dicament en France. Quinze de ses membres viennent de claquer la porte du Leem, en raison de divergences sur la strat\u00e9gie \u00e0 adopter pour d\u00e9fendre les int\u00e9r\u00eats du secteur. Sept d\u2019entre eux, tous des laboratoires fran\u00e7ais parmi lesquels figure\u00a0Sanofi<\/a>, l\u2019unique poids lourd de la pharmacie en France, s\u2019appr\u00eatent \u00e0 fonder un syndicat concurrent. \u00ab\u00a0Guerbet, Ipsen, LFB, Pierre Fabre, Sanofi, Servier et Th\u00e9a ont d\u00e9cid\u00e9 d\u2019\u00eatre \u00e0 l\u2019initiative de la cr\u00e9ation prochaine d\u2019un nouveau syndicat de l\u2019industrie pharmaceutique en France, centr\u00e9 sur l\u2019acc\u00e8s des patients fran\u00e7ais aux m\u00e9dicaments innovants et la reconnaissance de l\u2019empreinte de R&D et de production en France\u00a0\u00bb, expliquent les s\u00e9cessionnistes.\u00a0Parmi les autres laboratoires ayant claqu\u00e9 la porte du Leem figurent UPSA, Biocodex ou Mayoly pharma.<\/p>\n

Le Leem est par nature l\u2019organe de repr\u00e9sentation d\u2019entreprises (280 au total) aux int\u00e9r\u00eats divergents. Il compte des laboratoires fran\u00e7ais et \u00e9trangers, des entreprises produisant en France et d\u2019autres d\u00e9pourvues d\u2019usines. \u00ab\u00a0Nous avons toujours essay\u00e9 de trouver un \u00e9quilibre entre les int\u00e9r\u00eats des uns et des autres, explique Thierry Hulot, le pr\u00e9sident du Leem. C\u2019\u00e9tait plus facile lorsque nous n\u2019\u00e9tions pas soumis \u00e0 une contrainte budg\u00e9taire de dingue.\u00a0\u00bb\u00a0<\/p>\n


\n Passer la publicit\u00e9
\n<\/a> <\/p>\n

Le programme du nouveau syndicat est clair\u00a0: d\u00e9fendre la production de m\u00e9dicaments innovants en France. Le Leem, \u00e0 leurs yeux, n\u2019a qu\u2019insuffisamment promu le maintien d\u2019une production hexagonale. Un autre syndicat, constitu\u00e9 par des laboratoires fran\u00e7ais ayant quitt\u00e9 le Leem mais fabriquant dans l\u2019Hexagone des m\u00e9dicaments matures, sera \u00e9galement cr\u00e9\u00e9.<\/p>\n

Pour l\u2019instant, ce sont les laboratoires fran\u00e7ais contre le reste du monde. Mais les d\u00e9missionnaires esp\u00e8rent bien convaincre d\u2019autres laboratoires, fran\u00e7ais ou non \u00e0 condition qu\u2019ils produisent en France, de les rejoindre.<\/p>\n","protected":false},"excerpt":{"rendered":"Un nouveau syndicat de l\u2019industrie pharmaceutique en France s\u2019appr\u00eate \u00e0 voir le jour pour d\u00e9fendre les int\u00e9r\u00eats du…\n","protected":false},"author":2,"featured_media":650884,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[631,627,630,340,398,35,343,634,405,629,636,33,34,632,638,1011,27,637,399,639,635,401,628,633,407],"class_list":{"0":"post-650883","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-economie","8":"tag-action","9":"tag-actions-francaise","10":"tag-actualite-bourse","11":"tag-bourse","12":"tag-bourse-de-paris","13":"tag-business","14":"tag-cac-40","15":"tag-cotation","16":"tag-cotations","17":"tag-cours-des-societes-francaises","18":"tag-devises","19":"tag-economie","20":"tag-economy","21":"tag-fcp","22":"tag-figaro","23":"tag-fr","24":"tag-france","25":"tag-indices","26":"tag-investissement","27":"tag-le-figaro","28":"tag-marches","29":"tag-sicav","30":"tag-societes-etrangeres","31":"tag-warrant","32":"tag-warrants"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@fr\/115863170852471318","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts\/650883","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/comments?post=650883"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts\/650883\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/media\/650884"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/media?parent=650883"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/categories?post=650883"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/tags?post=650883"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}